LIVN

NASDAQ Healthcare

LivaNova PLC - Ordinary Shares

Medical Devices

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

๐Ÿ“Š Market Data
Price$61.00
Volume632,347
Market Cap3.35B
Beta0.970
RSI (14-Day)37.6
200-Day MA$58.58
50-Day MA$64.17
52-Week High$71.92
52-Week Low$35.00
Forward P/E13.34
Price / Book2.78
๐ŸŽฏ Investment Strategy Scores

LIVN scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 35/100โ–ฒ +1
High dividend yield + low volatility
๐Ÿš€ Moon Shot 73/100โ–ฒ +2
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 72/100โ€” 0
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 12/100โ–ผ -2
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿš€ Moon Shot (73/100) โ€” this strategy High growth potential (high beta + oversold).

Lowest fit among scored strategies: ๐ŸŽˆ Over-Hyped (12/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find LIVN in your text

Paste any article, transcript, or post โ€” the tool will extract LIVN and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.